Introduction
Pancreatic adenocarcinoma has a poor prognosis attributed to extensive invasion and metastasis through lymphatic channels, blood vessels, and along peripheral nerves (Bockman et al., 1994; Schneider et al., 2001) . Of these, perineural spread is the most common route of invasion (Yi et al., 2003) , with an incidence ranging between 84 and 100% (Bockman et al., 1994) .
Nerve growth factor (NGF) is a neurotrophic cytokine that controls axonal chemotaxis, growth, differentiation, and survival of a variety of neural cell types (Bothwell, 1995; Barrett, 2000) . Two sets of NGF receptors, a high-affinity TrkA and a low-affinity p75 NGFR , have been identified. The binding of NGF to TrkA induces phosphorylation of an intracellular tyrosine kinase and activation of signaling pathways that, in turn, induce numerous biologic effects (Hempstead et al., 1991; Bothwell, 1995; Barrett, 2000) . NGF and its receptors are expressed in neural tumors like neuroblastoma (Nakagawara et al., 1992; Suzuki et al., 1993) and glioma (Eberhart et al., 2001 ) and also in nonneural tumors like prostate (George et al., 1998) , breast (Descamps et al., 2001) , lung (Ricci et al., 2004) , and pancreatic cancers (Zhu et al., 2002) , suggesting that the NGF-TrkA signaling system is frequently involved in cell migration, growth, and survival during cancer progression. Although reports are not consistent, immunohistochemical studies have revealed that TrkA expression is observed mainly in the cytoplasm of pancreatic cancer cells, whereas intense NGF and p75 NGFR expression is observed in the peripheral nerve (Miknyoczki et al., 1999; Zhu et al., 1999; Sakamoto et al., 2001) . Enhanced or aberrant expression of the NGF-TrkA system in pancreatic cancer is, therefore, considered to be related to the perineural invasion of cancer cells (Zhu et al., 1999) .
Aberrant CpG methylation, on the other hand, controls gene expression in many human cancers (Ehrlich, 2002) . During carcinogenesis and cancer progression, gene silencing by global hypermethylation of CpG islands in the promoter region is observed in many genes related to the cell cycle (p16  INK4a and  p15 INK4b ), DNA repair (hMLH1, MGMT, and BRCA1), cell adherence and metastatic processes (CDH1, TIMP3, DAPK), the p53 network (p14 ARF and p73), metabolic enzymes (GSTP1), and the APC/b-catenin pathway (APC) (Esteller et al., 2001) . Global genomic hypomethylation, which is linked to DNA instability and oncogene activation, has also been found in many types of human cancers including prostate, liver, and uterine tumors (Clark and Melki, 2002; Ehrlich, 2002) . Little attention has been paid, however, to the role of the methylation status of non-CpG islands during cancer progression mainly because of the technical difficulties of epigenetic studies with a small subset of the population selected by morphologic observation.
To clarify the epigenetic mechanism that controls TrkA gene expression during pancreatic cancer progression, we characterized the TrkA gene promoter region by sodium bisulfite mapping of microdissected pancreatic cancer specimens obtained at autopsy and surgery, as well as of various types of cancer cell lines. The results showed that methylation of non-CpG islands around the negative regulating AP-1-like site in the 5 0 -untranslated region of the TrkA gene was positively related to the expression of the gene.
Results

Cloning and construction of the TrkA luciferase gene construct
Cloning the sequence further upstream of the reported TrkA promoter (Indo et al., 1997) yielded a 1.7-kb fragment (GenBank AY321513). Although the fragment did not contain canonical binding sites for the major transcription factors, CpG clusters and one AP-1-like site (TGAGCGA) were observed between the transcription and translation start sites (Figure 3c ).
Steady-state TrkA mRNA expression and promoter activity
Steady-state TrkA mRNA expression was highest in SK-N-SH (13.6), followed by SW480 (7.5), relatively low in HT29 (4.1), MIAPaCa2 (4.8), COLO320 (2.4), and PANC1(1.0) (Figure 1a ). To determine whether it correlated with transcription in vivo, TrkA promoter activity was assessed in the cell lines. Except for its correlation with two pancreatic cell lines, the promoter activity of the exogenously transfected whole TrkA promoter region (AP-1 ( þ )) demonstrated no correlation with the endogenous steady-state expression of any of the other cell lines. Relative luciferase activity of the TrkA promoter was highest (18.62) in COLO320, lowest (3.25) in PANC1, and intermediate in the 9.31 in MIAPaCa2, 8.77 in SW480, and 7.24 in HT29) (Figure 1b ). These differences between exogenous and endogenous gene expression led us to assume the presence of epigenetic mechanisms that control TrkA gene expression.
Mapping methylation status by Southern blot screening and sodium bisulfite modification
Since the TrkA promoter contains CpG loci clustering around the transcription and translation start sites (Figure 2a) , the methylation state of the loci was examined for cis-regulatory elements. The methylation status of the TrkA 5 0 -flanking region was first examined by Southern blot analysis. When probed with a DNA fragment covering the 5 0 flanking region (À1637 to þ 53), HpaII digestion showed several methylationprotected bands in DNA from MIAPaCa2, SW480, HT29, and SK-N-SH, but not in that from PANC1, COLO320, and the placenta (arrows, Figure 2b ). On the other hand, only a few minor protected bands were seen (arrows, Figure 2c ) when probed with a DNA fragment covering the upper two-thirds of the cloned fragment (À1637 to À511). To obtain more precise information about the methylation status, especially upstream of the basic promoter and around the transcription and translation start sites, methylated CpG sites were mapped by sodium bisulfite modification. Reflecting Southern blot analyses, CpG loci upstream of the basic promoter were almost unmethylated in the six cell lines (Figure 3b ), while numerous methylated-CpG loci, especially at the 5, 6, and 7th CpG loci, were observed in MIAPaCa2 and SK-N-SH ( Figure 3d ) with a high level of steady-state expression of the TrkA mRNA ( Figure 1a) . In colon cancer cell lines, the number of methylated cytosine residues was greater in HT29
Figure 1 (a) Steady-state TrkA mRNA expression was highest in SK-N-SH (13.6), followed by SW480 (7.5), relatively low in HT29 (4.1), MIAPaCa2 (4.8), COLO320 (2.4), and PANC1 (1.0). (b) The whole extended 1.7-kb fragment of the TrkA gene promoter (AP-1 ( þ )) was used for transient transfection studies. and SW480 than in COLO320, although there was considerable heterogeneity in methylation status among the 10 independent clones of each cell line.
MIAPaCa2 cells treated with 5-aza-dC yielded reduced steady-state TrkA mRNA expression (Figure 4a ), where numerous methylated CpGs in the TrkA promoter were observed before treatment (Figure 3d ). On the other hand, the treatment did not affect the expression in PANC1 (Figure 4a ), where methylated CpG sites were sparsely observed, even before treatment ( Figure 3d ). The level of GAPDH is shown as a standard (Figure 4a ).
Sss I methylase treatment, site-directed mutagenesis, and 12-O-tetradecanoylphorbol-13-acetate (TPA) and Calphostine C (Cal C) treatment
After Sss I treatment (Sss I ( þ )), the relative luciferase activity of the Mut (À) construct was markedly elevated in the three cell lines tested (Figure 4b ). Moreover, the construct containing the mutated AP-1-like site (Mut ( þ )) exhibited even higher promoter activity than the Mut (À) construct in each of the three cell lines. The maximal promoter activities yielded by the mutation construct were, however, attenuated to those of the Mut (À) Sss I ( þ ) level after Sss I treatment (Mut ( þ ) Sss I 
Electrophoretic mobility shift assay (EMSA)
EMSA was carried out to examine the binding of regulatory proteins to the AP-1-like sequence (boxed in Figure 3c ) between the transcription and translation start sites. Oligonucleotides corresponding to the AP-1-like sequence without methylated CpG formed a specific DNA-protein complex that was mainly supershifted by anti-c-Jun antibodies, and partly blockshifted by antiJunD and -Fra2 antibodies ( Figure 5a ). Introduction of a single methylated-CpG dinucleotide within the AP-1-like site (TGAGCGA) per se did not affect the DNA binding of the transcription factors ( Figure 5b ). EMSA with fully methylated oligonucleotides, on the other hand, did not form any protein complex that was either supershifted or blockshifted by the antibodies (Figure 5c ). Unlabeled excess oligonucleotide containing the consensus AP-1 or the AP-1-like site competed for binding with the labeled probe, while one containing the methylated AP-1-like site could not ( Figure 5d ).
Chromatin immunoprecipitation (ChIP) assay
Although 5-aza-dC treatment decreased TrkA expression in SK-N-SH cells (Figure 4a ), it left the total amount of the acetylated histones (H3 and H4) unchanged ( Figure 6 ), indicating that the chromatin structure around the TrkA gene promoter area remained relaxed irrespective of the level of TrkA steady-state expression.
Immunohistochemistry, microdissection, and sequencespecific methylation analysis by bisulfite mapping
To determine whether methylation around the TrkA transcription and translation start sites actually correlated with the expression in the normal pancreas and in pancreatic cancer, TrkA expression was evaluated immunohistochemically using tissue specimens from stage IV pancreatic ductal adenocarcinomas and the control pancreas taken at autopsy. In six of the eight cases, TrkA was observed mainly in cancer cells, whereas only weak TrkA expression was detected in the peripheral nerve and in normal endocrine and exocrine pancreas. The remaining two TrkA-negative pancreatic cancers (cases 5 and 6 in Table 1 ) were ne1 and ne0 showing no or low-grade perineural invasion. Negative controls prepared with nonimmunized rabbit serum did not show any significant staining. Of the histopathological and immunohistochemical findings in Table 1 , a representative case (case 1) of pancreatic ductal cancer is shown in Figure (b) Effects on TrkA promoter activity by Sss I methylase (Sss I ( þ )) and/or the mutated AP-1-like site (Mut ( þ )) was measured by Luciferase assay. After Sss I treatment (Sss I ( þ )), the relative luciferase activity was markedly elevated in all the cell lines tested, and the construct containing mutated AP-1-like site (Mut ( þ )) showed even higher promoter activity than the Mut (À) construct in each cell line. However, the maximal promoter activities yielded by the mutation were attenuated to those of Mut (À) Sss I ( þ ) level after Sss I treatment (Mut ( þ ) Sss I ( þ )). Bars indicate mean7s.d. of six independent samples. (c) Treatment with Cal C, an inhibitor of protein kinase C, upregulated promoter activity, whereas with TPA, a PTC agonist, suppressed it when the wild-type construct was used without Sss I methylase treatment (Mut (À) Sss I (À)). TPA and Cal C, however, did not affect the promoter activity of constructs, which were methylated (Mut (À) Sss I ( þ )) or mutated at the AP-1-binding site (Mut ( þ ) Sss I (À)). Bars indicate mean7s.d. of six independent samples the immunohistochemical observation. Comparing the normal pancreas with cancer tissue and the invasion front where cancer showed extensive perineural invasion and strong TrkA immunostaining, methylated CpG tended to accumulate around the AP-1-like sequence (CpGs numbered 5, 6, and 7) in cases of progressing stage IV pancreatic ductal cancers (Figure 8 ). Although only two cases of TrkA-negative pancreatic cancer cases are included (cases 5 and 6 in Table 1 ), methylation was scattered almost randomly, and no accumulation of the methylated CpG (at 5, 6, and 7) was observed (data not shown).
Discussion
The mechanisms regulating the expression of TrkA, a high-affinity NGF receptor, were analysed during cancer progression. In cell lines, steady-state TrkA mRNA expression, assessed by quantitative real-time Transcriptional regulation by DNA methylation is typically observed in CpG islands located around the promoter region. This process is usually mediated through a sequence-independent process, involving the binding of methyl CpG-binding proteins to methylated CpG islands and the recruitment of histone-modifying enzymes followed by chromatin compaction and gene silencing (Jones and Laird, 1999; Wade, 2001) . DNA methylation, on the other hand, can alter gene expression through a change in the binding affinity of sequence-specific transcriptional factors by protruding into the major groove structure (Razin and Cedar, 1991) . Previously, only a limited range of transcription factors such as E2F (Campanero et al., 2000) was considered to be affected by methylation because the CpG dinucleotide sequence within the binding site was thought to be essential. More recently, however, we (Kitazawa et al., 1999) and others (Zhu et al., 2003) have reported that CpG methylation adjacent to transcription factor-binding sites can either directly or indirectly through methylation-dependent, sequence-specific DNA-binding proteins (Zhang et al., 1986 ) also affect the DNA binding of transcription factors. Therefore, CpG methylation in non-CpG islands, the role of which has not yet been well evaluated in cancer progression, could contribute to minimum alteration of the specific gene expression at the transcription level by altering the affinity of the transcription factors to the DNA.
Except for the report by Eden et al. (2001) that methylation of an upstream repressor element of the imprinted Igf2 gene is indirectly associated with gene reactivation, methylation is usually associated with gene silencing. In our current study, to explain the mechanism whereby methylation promotes TrkA transcription, we hypothesized that either (a) the negative regulatory AP-1 site is inactivated by methylation itself or by transcriptional repressors or, (b) the sequence modified by methylation is recognized as a new positive regulating AP-1-binding site as previously described (Tulchinsky et al., 1996) . The promoter-reporter construct with mutated AP-1-binding site (Mut ( þ )) showed the highest transcriptional activity in all the transfected cell lines tested, indicating that this AP-1-binding site functions as a negative cis-regulatory element for TrkA expression (Figure 4b) . Indeed, AP-1, characterized mostly as a transcriptional activator, is also known to act as a transcriptional repressor of some target genes through its direct binding to the AP-1-binding site (Brellier et al., 2004) . Furthermore, c-Jun homodimers bound mainly to oligonucleotides corresponding to the AP-1-binding site, which was completely blocked by Sss I methylase-induced full methylation, as shown by EMSA (Figure 5c ). Interestingly, induction of methylation of a single CpG dinucleotide within the AP-1-binding site per se did not affect the DNA binding of the transcription factors (EMSA study, Figure 5b ). These data demonstrated that induction of methylation not within but adjacent to the AP-1-binding site directly blocks the binding of AP-1 complexes, resulting in an upregulation of TrkA gene expression by the blockage of the negative regulatory cis-element. As some methylation-sensitive transcription factors like E2F can be both activating and repressing (Attwooll et al., 2004) , selective methylation at specific transcription factor-binding sites can also be both repressing and activating. Moreover, because methylation adjacent to the transcription factor-binding site can block the binding of some methylation-insensitive transcription factors like Sp1 (Zhu et al., 2003) and AP-1 (present report), we speculate that sporadic methylation at or adjacent to the transcription factorbinding site located in non-CpG islands can modulate the gene expression, both negatively and positively, without affecting the global chromatin structure. We next focused on the clinicopathological study using pancreatic cancer specimens obtained at surgery or autopsy to determine whether the difference in TrkA expression during cancer progression could also be epigenetically interpreted, as was observed in vitro. As has been reported by others (Miknyoczki et al., 1999; Sakamoto et al., 2001) , immunohistochemical analysis showed that TrkA was strongly expressed in most stage IV pancreatic ductal cancer cells (a representative case shown in Figure 7) , especially with extensive perineural invasion. Based on these immunohistochemical observations, bisulfite mapping was conducted with our newly modified morphology-oriented technique (Kitazawa et al., 2000) on microdissected samples taken from nontumorous exocrine and endocrine pancreas, the center, and the invasion front (perineural invasion sites) of the cancer. Bisulfite mapping showed that methylated NGFR is expressed in peripheral neuron fibers. H.E. section is shown for reference Figure 8 Bisulfite genomic sequencing of the TrkA promoter region in human DNA selectively collected from normal pancreas and stage IV pancreatic cancer tissues by microdissection. The region analysed in exon 1 ( þ 21 to þ 129) is shown at the top. All CpG sites within the region (numbered 1-14) , the AP-1-like site (TGAGCGA), and the translation start site (ATG) are indicated. Methylated CpG gradually accumulated around the AP-1-like sequence in the primary lesion and at the perineural invasion site. Each pie chart corresponds to one CpG site shown in the upper schema, and the black slices represent percentages of methylated CpG from 10 independent sequences from bisulfite mapping using microdissected tissue samples listed as beads on string. Closed circles represent methylated CpGs, and open circles represent unmethylated CpGs. At least three independent microdissected samples from nontumorous exocrine and endocrine pancreas, the center, and the invasion front of the cancer in all eight cases with stage IV pancreatic ductal cancers were examined TrkA methylation in cancer progression M Fujimoto et al CpG tended to accumulate just downstream of the AP-1-like sequence (CpGs numbered 5, 6, and 7 in Figure 8 ) in cancer cells with high TrkA expression assessed by immunostaining (Figure 7) . Although a limited number of stage IV cases were analysed, higher methylation was observed at the perineural invasion site than at the center of the tumor, suggesting that the correlation between methylation and TrkA expression is not confined to an in vitro event but is also valid in vivo during pancreatic cancer progression. We therefore speculate that TrkA expression in pancreatic cancer cells is regulated by an epigenetic event, conferring versatility and plasticity to TrkA gene expression during cancer progression, and playing a crucial role in cancer invasion around peripheral nerve fibers. As methylation other than 5-7th CpGs is frequently observed in the normal pancreas and does not correlate with TrkA expression in cancer cell lines or pancreatic cancer specimens, those aberrant CpG methylations around the 10-14th loci are probably not significant for TrkA expression. Further accumulation of methylation around the promoter can result in global CpG methylation, however, leading to the condensation of the chromatin structure (Bird and Wolffe, 1999) and to the silencing of TrkA gene expression. Thus, epigenetic regulation of the TrkA gene can be transient and unstable. Furthermore, the in vitro observation that TrkA expression was also epigenetically regulated in colorectal cancer cell lines indicates that the NGF-TrkA system could be involved in the progression of other cancers. Heterogeneity of cancer cells could occur during the invasion from the primary site to surrounding tissues in order to adapt to an altered microenvironment, and may be stabilized by subsequent subclonal selection according to subtle epigenetical differences including methylation of non-CpG islands before the occurrence of global methylation of CpG islands and/or genetic alteration. Therefore, to evaluate subtle epigenetic alteration of non-CpG islands among minor subclonal populations, morphology-oriented epigenetic analysis using microdissected samples is requisite, especially where heterogeneity and plasticity are as notable as in pancreatic cancer.
Materials and methods
Cell lines
Two human pancreatic cancer cell lines (PANC1 and MIAPaCa2) and three human colon cancer cell lines (COLO320, SW480, and HT29) were cultured in RPMI1640, and one human neuroblastoma cell line (SK-N-SH) was cultured in aMEM. The media were supplemented with 10% FBS, 100 U/ml penicillin, and 100 U/ml streptomycin. All cell lines were maintained at 371C in a humidified atmosphere with 5% CO 2 .
Cloning of TrkA 5
0 -flanking region
The 5 0 -flanking region of the human TrkA gene was cloned by a PCR-based method using the Genome Walker kit (Clontech, Palo Alto, CA, USA). Antisense primers (TrkA1 and nested TrkA2), designed from the published human TrkA sequence (GenBank AB019480) (Indo et al., 1997) , were as follows:
Two DNA fragments were generated by PCR: the whole extended 5 0 -flanking region, including the 5 0 -untranslated region (À1637 to þ 83, AP-1 ( þ )), and a deletion construct lacking the AP-1-binding site located between the transcription and translation start sites of the TrkA gene (À1637 to þ 53, AP-1 (À)). Both fragments were ligated into a promoterless and enhancerless pGL3-Basic vector plasmid (Promega, Madison, WI, USA). At least three independent clones were sequenced by an ABI prism 310 Genetic Analyzer (PerkinElmer, Norwalk, CT, USA) from both ends.
Transient transfection studies
The plasmid construct was cotransfected with the pRL-TK vector (Promega) into the cell lines using Effectenet Transfection Reagent (Qiagen, Valencia, CA, USA), according to the manufacturer's instructions. The cells were washed with phosphate-buffered saline (PBS) 6 h after transfection, then lysed with Passive Lysis Buffer (Promega) and harvested 24 h after transfection. Firefly and Renilla luciferase activities of the lysates from transfected cells were measured with an ATP-3010 luminometer (Advantec, Tokyo, Japan), according to the Dual-Luciferaset assay protocol. The transfection efficiency of each construct was evaluated by determining the activity of Renilla luciferase. The transfection study was repeated three times and representative data are expressed as the mean7s.d. of relative luciferase activity standardized by TK promoter activity from six culture wells.
RNA extraction, quantitative real-time (Q-RT)-PCR and reverse transcription (RT)-PCR
In total, 1 mg of total RNA, isolated from each cell line, was reverse transcribed to produce cDNA, which was then amplified and quantified by the ABI PRISM 7300 Real-Time PCR system (Applied Biosystems, Foster city, CA, USA) using a set of primers and probes (assay ID: Hs00176787ms) purchased from Applied Biosystems. The amount of mRNA was quantified relative to that of GAPDH in each reaction according to the manufacturer's protocol (Applied Biosystems). RT-PCR was also conducted using 1 mg of total RNA and the following sets of primers:
The PCR conditions were as follows. Denaturation at 941C for 2 min, 30 cycles of 941C for 30 s, 581C for 30 s, 721C for 1 min, and a final elongation step of 5 min at 721C. The amplified PCR products were loaded onto a 3% agarose gel.
Southern blotting for screening CpG methylation status
Genomic DNA was extracted from the six cell lines (PANC1, MIAPaCa2, COLO320, SW480, HT29, and SK-N-SH) and from human placenta by standard protocols. In total, 10 mg of each DNA was digested for 24 h at 371C with 3 ml of either MspI or HpaII, electrophoresed and transferred onto high bond N þ nylon membranes (Amersham Biosciences Corp., Piscataway, NJ, USA). Fragments of the 5 0 -flanking region of the TrkA gene (À1637 to þ 53 and À1637 to À511, Figure 2a) were used as probes. The membranes were hybridized at 651C for 12 h, washed twice in 2 Â SSPE containing 0.1% SDS, twice in 1 Â SSPE containing 0.1% SDS, finally once in 0.1 Â SSPE containing 0.1% SDS at 651C, and then analysed with a BAS-2000 image analyser (FUJIX, Tokyo, Japan).
DNA extraction and bisulfite modification
The bisulfite reaction was carried out as described (Frommer et al., 1992; Olek et al., 1996; Kitazawa et al., 2000) . Lowmelting agarose beads (10 ml), containing 0.5 mg genomic DNA derived from each cell line, were formed in mineral oil and denatured with NaOH (final concentration, 0.1 M). The beads were dipped in 1 ml of freshly prepared bisulfite solution containing 1 mM hydroquinone and 3.5 M NaHSO 3 at pH 5. The liquid surface was sealed with mineral oil, and the samples were incubated for 16 h at 501C. The beads were then washed with Tris-EDTA, desulfonated with 0.5 N NaOH for 30 min, neutralized with 1 N HCl, and finally washed with Tris-EDTA. Bead fragments containing up to 0.1 mg DNA were used for PCR. The 245-and 163-bp DNA fragments corresponding to the approximately 300 bp upstream of the basic promoter ( Figure 3a ) and to the area between the transcription and translation start sites (Figure 3c ) of the TrkA gene were amplified by PCR using the following sets of primers:
TrkA5 ( The PCR conditions were as follows. Denaturation at 951C for 1 min, 35 cycles of 951C for 30 s, 651C for 30 s, 701C for 1 min, and a final elongation step of 5 min at 701C. The amplified DNA was cloned into the TA Vector (Invitrogen, Carlsbad, CA, USA). At least 10 independent clones were selected and sequenced.
5-Aza-dC treatment
Steady-state TrkA mRNA expression was examined in PANC1, MIAPaCa2, and HT29 cells with or without 5-azadC treatment, while changes in the methylation status of the TrkA promoter region were monitored by sodium bisulfite mapping. Exponentially growing cells were seeded at a density of 1.5 Â 10 6 cells/100 mm-diameter dish and allowed to attach overnight. The cells were then treated with freshly prepared 1 mM 5-aza-dC (Sigma, St Louis, MO, USA) (day 0). After 24 and 72 h (day 1 and day 3), the cells were washed twice with PBS and treated with fresh medium without 5-aza-dC. After 120 h (day 5), genomic DNA and total RNA were collected from each dish and purified by standard methods. After confirming that all CpG loci in the TrkA 5 0 -flanking region were completely demethylated, RNA was used as a template for semiquantitative RT-PCR to evaluate TrkA mRNA levels.
Sss I methylase treatment, site-directed mutagenesis, and TPA and Cal C treatment For in vitro methylation studies, the plasmid construct with the TrkA promoter-luciferase reporter gene was treated with Sss I CpG-methylase (New England Biolabs, Beverly, MA, USA) in the presence of 160 mM S-adenosylmethionine. The plasmid constructs were transfected into PANC1, MIAPaCa2, and SK-N-SH cells, and the promoter activity was determined by the Dual-Luciferaset assay. Similarly, both unmethylated and methylated pGL3-Basic vector plasmids (Promega) were used as standards. Relative luciferase activities were measured by the same method. Site-directed mutagenesis was carried out by the recombinant PCR technique (Kondo et al., 2004) so that the AP-1-like site (TGAGCGA) in the TrkA promoter gene was replaced with (TATTGTA). The sequence of the mutant construct was confirmed by direct sequencing to eliminate PCR-related mutations. The mutant construct with the TrkA promoter-luciferase reporter gene was also treated with Sss I CpG-methylase, and the promoter activity was measured by the above-mentioned method. In the course of culturing, some of the SK-N-SH cells were treated with freshly prepared solutions of 12-O-tetradecanoylphorbol-13-acetate (TPA, Sigma-Aldrich, St Louis, MO, USA, 10 100 nM) or with Calphostine C (CalC, Calbiochem, San Diego, CA, 10 mM) for 24 h and used for comparison.
EMSA
Nuclear extracts were prepared from SK-N-SH cells. For EMSA, the following pairs of complementary oligonucleotides, which contain the AP-1-like site ( þ 52 to þ 91) or the consensus AP-1 sequence, were synthesized for annealing:
TrkA9 ( 
ChIP assay
According to the instructions of Acetyl-Histone H3/H4 Immunoprecipitation Assay Kit (Upstate Biotechnology, Lakeplacid, NY, USA), soluble chromatin was prepared from 1 Â 10 6 cells fixed with formaldehyde, precleared with salmon sperm DNA/protein A agarose-50% slurry, then 2 ml of supernatant solution was incubated with antiacetyl-Histone H3 antibody or antiacetyl-Histone H4 antibody overnight at 41C with rotation. Immunoprecipitates were collected after salmon sperm DNA/protein A agarose slurry treatment (60 ml) for 1 h at 41C with rotation, and then washed as described. From eluted immunoprecipitates, DNA was recovered by phenol/chloroform extraction and ethanol precipitation and resuspended with 30 ml of 1 Â TE. DNA solution (2 ml) was used as a template for PCR. PCR was conducted using the following set of primers:
TrkACI-1 (sense):
Immunohistochemistry Formalin-fixed, paraffin-embedded tissue from stage IV pancreatic ductal cancer specimens (n ¼ 8) taken at surgery (n ¼ 4) and autopsy (n ¼ 4) in our department over the last 3 years were used (seven men, one woman; 54-67 years old; mean 62.5.74.9 years) ( Table 1 ). The study was reviewed and approved by the local ethics committee at Kobe University. The specimens were deparaffinized in xylene and rehydrated in a series of graded ethanol. Antigen was retrieved by microwave treatment at 350 W for 10 min in 10 mM citrate buffer (pH 6.0). The slides were incubated in a mixture of 3% H 2 O 2 and methanol for 10 min at room temperature to block endogenous peroxidase activity. After treatment with blocking antibody, the primary antibodies were added and the slides were incubated for 60 min at room temperature. Rabbit polyclonal IgG raised against epitope mapping adjacent to the carboxyl terminus of human TrkA (Santa Cruz Biotechnology), rabbit polyclonal antibody raised against a peptide mapping at the amino terminus of the mature form of human NGF (Santa Cruz Biotechnology), and rabbit polyclonal antibody raised against a recombinant human p75 cytoplasmic domain (Promega) were used as primary antibodies. Nonimmunized rabbit serum was used for preparing negative controls. The avidin-biotin-peroxidase complex method was used with a DAKO LSAB kit (Glostrup, Denmark). Final development of the sections was carried out with 3,3 0 -diaminobenzidine (DAB) containing 0.03% H 2 O 2. Immunohistochemical staining was graded as negative (no staining), weakly positive (less than 30% of cells positive), positive (30-60% of cells positive), or strongly positive (more than 60% of cells positive with strong immunoreactivity).
Microdissection and bisulfite modification
Sections (7-mm thick) were cut from formalin-fixed and paraffin-embedded human pancreatic ductal adenocarcinoma samples and stained with hematoxylin and eosin. The laser capture microdissection system (LM200, Olympus, Tokyo, Japan) was used to select cells from the normal endocrine pancreas (n ¼ 3), and the exocrine pancreas consisting of acinar cells and intercalated ducts (n ¼ 3), and from each case of pancreatic cancer (n ¼ 8, Table 1 ), consisting of the center of the cancer mass and the site of perineural invasion. At least three independent microdissected samples from each portion were analysed for sodium bisulfite mapping. Dissected samples were lysed overnight in 25 ml of lysis solution containing 0.2 mg/ml Proteinase K, 10 mM Tris-HCL (pH 8.0), 10 mM EDTA, and 1% Tween 20. In all, 10 ml of low-melting agarose beads containing 7.5 ml of cell lysate were formed (final 1.6%), and methylated CpG was analysed by the sodium bisulfite method as described above. Bead fragments were analysed by nested PCR using the following sets of primers:
TrkA11 ( The first PCR conditions were as follows. Denaturation at 951C for 1 min, 35 cycles of 951C for 30 s, 651C for 30 s, 701C for 1 min, and a final elongation step of 5 min at 701C. The nested PCR conditions were as follows. Denaturation at 951C for 1 min, 35 cycles of 951C for 30 s, 551C for 30 s, 701C for 1 min, and a final elongation step of 5 min at 701C. PCR products were ligated into a TA vector, and at least 10 independent clones were sequenced.
